Second chance: new combo tackles hepatitis c in HIV patients
NCT ID NCT00221650
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of peginterferon alfa2a and ribavirin in 17 HIV-positive people with chronic hepatitis C who had not responded to earlier treatment. Participants received weekly injections and daily pills for 48 weeks. The main goal was to see if the virus became undetectable 24 weeks after treatment ended.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
peginterferon alfa2a and ribavirin
What this could lead to
If successful, this could offer a second-line treatment option for hepatitis C in people with HIV who did not respond to initial therapy.
What could go wrong
This is a very small, early-phase study (17 participants) with no control group. Results may not apply broadly, and the combination can cause flu-like symptoms, anemia, and depression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS C, CHRONIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Pellegrin, Federation des Maladies Infectieuses, Pr RAGNAUD
Bordeaux, 33076, France